Metropolitan Life Insurance Company (MetLife)’s Crescent Biopharma CBIO Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-117	Closed	-$140K	–	2593
2019 Q2	$140K	Hold	117	–	–	﹤0.01%	2130
2019 Q1	$146K	Hold	117	–	–	﹤0.01%	2098
2018 Q4	$111K	Hold	117	–	–	﹤0.01%	2203
2018 Q3	$169K	Hold	117	–	–	﹤0.01%	2123
2018 Q2	$189K	Buy	+117	New	+$201K	﹤0.01%	1975

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CBIO Position: Q3 2019 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Crescent Biopharma (CBIO) in Q3 2019, closing a stake of 117 shares — an estimated $140K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CBIO in Q2 2018 and held it in 5 quarters. The position peaked at $189K in Q2 2018. 75 funds tracked by Wall St. Rank hold CBIO as of Q3 2019.

Metropolitan Life Insurance Company (MetLife) reported no remaining Crescent Biopharma position as of Q3 2019 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 117 Crescent Biopharma shares in Q3 2019, an estimated $140K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Crescent Biopharma in Q2 2018 and held it in 5 quarters.
Metropolitan Life Insurance Company (MetLife)'s Crescent Biopharma position peaked at $189K in Q2 2018.
75 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2019.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2019, filed 14 Nov 2019.